3,4-methylenedioxyamphetamine, or MDA, is a psychedelic hallucinogenic drug and empathogen/entactogen of the phenethylamine family. It was first synthesized by G. Mannish and W. Jacobson in 1910. There are about 20 different synthetic routes described in the literature for its preparation.
Medical use
MDA was first used in
animal tests in
1939, and
human trials began in
1941 in the exploration of possible therapies for
Parkinson's disease. From
1949 to
1957, more than 500 human subjects were given MDA in an investigation of its potential use as an
antidepressant and/or
anorectic by
Smith, Klein, and French. The
United States Army also experimented with the drug, code named EA-1298, while working to develop a
truth drug or incapacitating agent. One human subject died in January
1953 after being intravenously injected with 500mg of the drug. MDA was patented as a
cough suppressant by H. D. Brown in 1958, as an
ataractic by
Smith, Klein, and French in 1960, and as an
anorectic under the trade name “Amphedoxamine” in
1961. Several researchers, including
Claudio Naranjo, have explored MDA in the field of
psychotherapy.
Recreational use
MDA began to appear on the
recreational drug scene around
1963 to
1964. It was then inexpensive and readily available as a
research chemical from several scientific supply houses. Although now illegal, MDA continues to be bought, sold, and used for recreational purposes, often in the form of
tablets purporting to contain
MDMA (Ecstacy).
Effects
A recreational dose of MDA is commonly between 80 and 160mg. The “R”
optical isomer is more potent than the “S”
optical isomer. Although there is some debate, the duration of the drug is now generally believed to be roughly 6 to 10 hours(In the late 90s, Shulgin changed his opinion of the duration to 3-6 hours). The effects of the drug are quite similar to those of
MDMA (Ecstacy), including
empathogen/entactogenic effects, though typically less intense than a similar dosage of
MDMA. Because of these effects, MDA was called the “hug drug” and was alleged to stand for “Mellow Drug of America” in the
1960s. Some users feel that MDA has more
psychedelic or
hallucinogenic qualities than
MDMA.
The toxicity of MDA is not fully known. The LD50 in mice has been reported as 92mg/kg by intraperitoneal injection. Erowid lists the fatality rate at roughly 2 in 100,000 users. MDA is considered to be about 10x more neuro-toxic than its methylated cousin MDMA.
Legality
In
1970, the
Controlled Substances Act was enacted in the United States, placing MDA into
Schedule I. It is similarly controlled in other nations. Internationally, MDA is a Schedule I drug under the
Convention on Psychotropic Substances*.
See also
External links
References
- Lee, M.A. and Shlain, B., Acid Dreams: The CIA, LSD, and the Sixties Rebellion. Grove, 1985.
- Stafford, P. Psychedelics Encyclopedia. Ronin, 1992.
Categorization
Entactogens and Empathogens | Psychedelic phenethylamines | Schedule I controlled substances
3,4-Methylendioxyamphetamin | MDA | MDA (farmakologia)